Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

536.85 -23.16 (-4.14%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender ↗
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
News headline image
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. ↗
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. 
Via The Motley Fool
News headline image
Where Will Madrigal Pharmaceuticals Be in 3 Years? ↗
The coast is clear for it to grow, for now. 
Via The Motley Fool
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Is Madrigal Pharmaceuticals Stock a Buy? ↗
It's not the most prominent biotech, but it has an important claim to fame. 
Via The Motley Fool
News headline image
2 Under-the-Radar Growth Stocks to Consider ↗
Don't ignore these innovative companies. 
Via The Motley Fool
News headline image
1 No-Brainer Growth Stock to Buy Now ↗
This liver-disease specialist might be significantly undervalued. 
Via The Motley Fool
News headline image
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock ↗
This biotech just got clearance to dive into a deep ocean of a market. 
Via The Motley Fool
News headline image
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗
Success isn't guaranteed, but both companies could become big winners. 
Via The Motley Fool
News headline image
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
News headline image
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH ↗
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
News headline image
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug ↗
Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. 
Via Investor's Business Daily
News headline image
The Week Ahead: What's Next ↗
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
News headline image
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024 ↗
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of... 
Via TheNewswire.com
News headline image
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024 ↗
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
Via InvestorPlace
News headline image
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics ↗
These businesses should see good times ahead. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy in April 2024 ↗
Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. 
Via InvestorPlace
News headline image
2 Top Biotech Buyout Candidates ↗
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
News headline image
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗
Both stocks are pretty risky, but one of them more so than the other. 
Via The Motley Fool
News headline image
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? ↗
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? 
Via The Motley Fool
News headline image
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
News headline image
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? ↗
The mid-cap biotech has succeeded where many others failed. 
Via The Motley Fool
News headline image
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗
Madrigal has one key advantage over its two huge potential future rivals. 
Via The Motley Fool
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.